Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sensorion Announces Positive DSMB Recommendation for Phase 2a NOTOXIS Trial
Details : SENS-401 (R-azasetron besylate) is a 5-HT3 receptor antagonist, orally available small molecule, which is under clinical development for the treatment of Cisplatin-Induced Ototoxicity.
Brand Name : SENS-401
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 22, 2024
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sensorion Announces Positive Secondary Efficacy Data from SENS-401 Phase 2a Trial
Details : SENS-401 (arazasetron) is an orally available 5-HT3 receptor antagonist, small molecule drug. It is being evaluated in phase 2 clinical trials for the treatment of hearing loss.
Brand Name : SENS-401
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 15, 2024
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sensorion Meets Primary Endpoint for SENS-401 Phase 2a Study on Hearing Preservation
Details : SENS-401 (arazasetron) is an orally available 5-HT3 receptor antagonist, small molecule drug. It is being evaluated in phase 2 clinical trials for the treatment of hearing loss.
Brand Name : SENS-401
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 11, 2024
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sensorion Completes Patient Inclusion in SENS-401 Phase 2a Trial for Hearing Preservation
Details : SENS-401 (arazasetron) is an orally available 5-HT3 receptor antagonist, small molecule drug. It is being evaluated in phase 2 clinical trials for the treatment of hearing loss.
Brand Name : SENS-401
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 01, 2024
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SENS-401 (Arazasetron) is a 5-HT3 receptor antagonist and calcineurin inhibitor, orally available small molecule, which is under phase 2 clinical development for the treatment of Cisplatin-Induced Ototoxicity (CIO).
Brand Name : SENS-401
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 18, 2023
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SENS-401 (R-azasetron besylate), is a 5-HT3 receptor antagonist and calcineurin inhibitor, orally available small molecule that aims to protect and preserve inner ear tissue from damage responsible of progressive or sequelae hearing impairment.
Brand Name : SENS-401
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 03, 2023
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SENS-401 (arazasetron), is an orally available small molecule that aims to protect and preserve inner ear tissue from damage responsible of progressive or sequelae hearing impairment.
Brand Name : SENS-401
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 24, 2022
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SENS-401 (Arazasetron) is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequelae hearing impairment.
Brand Name : SENS-401
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 14, 2022
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SENS-401 (Arazasetron), is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequelar hearing impairment.
Brand Name : SENS-401
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 07, 2022
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SENS-401 (R-azasetron besylate) is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequelar hearing impairment.
Brand Name : SENS-401
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 01, 2022
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?